Miragen Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viridian Therapeutics

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VRDN" and its common stock will trade under a new CUSIP number, 92790C104.

miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor's Xtend™ half-life extension technology

miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Miragen has had years of disappointing share price performance with a cumulative loss of more than 90%. This is a reflection of the poor results in the two drug candidates that until recently composed its pipeline: Cobomarsen and Remlarsen.

Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity

BOULDER, Colo., Nov. 10, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biotechnology company advancing new treatments for patients with diseases that are underserved by current therapies, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates.

miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

It was thrilling to watch MGEN stock spike, and the bull move might not be over as Miragen's new acquisition puts high-need medicine in focus. The post Value-Added Acquisition Clears the Runway for Miragen Therapeutics appeared first on InvestorPlace.

Value-Added Acquisition Clears the Runway for Miragen Therapeutics

Miragen Therapeutics news of its acquisition of Viridian Therapeutics has MGEN stock skyrocketing on Wednesday. The post Miragen Therapeutics News: Why MGEN Stock Is Skyrocketing Today appeared first on InvestorPlace.

Miragen Therapeutics News: Why MGEN Stock Is Skyrocketing Today

Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED)

miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

miRagen decides to discontinue further internal development of cobomarsen miRagen decides to discontinue further internal development of cobomarsen

miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)

Lee Rauch appointed President and CEO, following resignation by William Marshall

miRagen Announces Leadership Transition and Review of Strategic Alternatives 

BOULDER, Colo., Aug.  20, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C meeting with the FDA Office of  Oncologic Diseases on August 11, 2020 to discuss miRagen’s future clinical development plans for cobomarsen for the potential treatment of Adult T-Cell Leukemia/Lymphoma (ATLL).

miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2020 Results - Earnings Call Transcript

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 29.41% and -74.23%, respectively, for the quarter ended June 2020.

Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Misses Revenue Estimates

BOULDER, Colo., Aug.  05, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the second quarter ended June 30, 2020 and provided business updates.

miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates

BOULDER, Colo., Aug.  04, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 1:10 p.m. ET.

miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Signal Genetics, Inc. (MGEN) Report Negative Earnings Next Week?

BOULDER, Colo., July  23, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. Cobomarsen is an inhibitor of miR-155 currently being developed by miRagen in two clinical programs to address different types of T-cell lymphoma, including a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell leukemia/lymphoma (ATLL).

Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma

BOULDER, Colo., July  22, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the financial markets close on Wednesday August 5, 2020.  

miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020

BOULDER, Colo., July  02, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.

miRagen Regains Compliance With Nasdaq Listing Requirements

Agenus

Atomera

Axcella Health Inc

EyePoint Pharmaceuticals

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Stocks To Hedge Your Portfolio With Amid Rising Coronavirus Cases

Key Opinion Leader call on IPF scheduled for 11 a.m. ET on Tuesday, June 23rd Key Opinion Leader call on IPF scheduled for 11 a.m. ET on Tuesday, June 23rd

miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis

BOULDER, Colo., June  18, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately. Ms. Rauch reports directly to President and Chief Executive Officer William S. Marshall, Ph.D., and is responsible for overseeing miRagen’s business development, licensing, partnerships, investor relations, corporate communications, intellectual property, and new product planning.

miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer

miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

Miragen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2020 Results - Earnings Call Transcript

Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

miRagen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q4 2019 Results - Earnings Call Transcript

News for Miragen Therapeutics Stock (MGEN)